Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPARE-VS: Vicadrostat vs spironolactone in heart failure / cardiovascular disease with chronic kidney disease
2025-523743-35-00Phase 2Authorised
- Sponsor
- University Medical Center Groningen
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of vicadrostat in heart failure (HF), cardiac morbidity, chronic kidney disease (CKD) and 1 more (2 arms), sponsored by University Medical Center Groningen. Planned start Mar 2026; status: authorised.
02
Drugs
vicadrostat
03
Conditions
heart failure (HF)cardiac morbiditychronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2025-523743-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523743-35-00.